Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 15/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 12/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.56 |
| ▸ | QPCT | Q16769 | 1/20 | 0.56 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.56 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.56 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7390727 | 0.79 | CYP11B1 (0.61) | CYP11B1CYP11B2CYP19A1POLBCYP1A2 | |
| SCHEMBL28750656 | 0.77 | CYP11B1 (0.55) | CYP11B1CYP11B2CYP19A1POLBCYP1A2 | |
| SCHEMBL7214592 | 0.76 | CYP11B1 (0.55) | CYP11B1CYP11B2CYP19A1POLBCYP1A2 | |
| SCHEMBL15179016 | 0.74 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1POLBCYP1A2 | |
| SCHEMBL30523908 | 0.74 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1POLBCYP1A2 | |
| SCHEMBL30523909 | 0.74 | CYP11B1 (0.76) | CYP11B1CYP11B2CYP19A1POLBCYP1A2 | |
| SCHEMBL8722517 | 0.73 | CYP11B1 (0.56) | CYP11B1CYP11B2CYP19A1POLBCYP1A2 | |
| SCHEMBL9221130 | 0.72 | CYP11B1 (0.48) | CYP11B1CYP11B2CYP19A1POLBCYP1A2 | |
| SCHEMBL7390725 | 0.72 | CYP11B1 (0.62) | CYP11B1CYP11B2CYP19A1POLBCYP1A2 | |
| SCHEMBL22063900 | 0.72 | CYP11B1 (1.00) | CYP11B1CYP11B2CYP19A1POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066647-B1 | BENZOXAZOLES AND OXAZOLOPYRIDINES BEING USEFUL AS JANUS KINASES INHIBITORS | NOVARTIS AG (CH) | 2011-11-09 | — | — | EP | claimed |
| US-6239220-B1 | Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. | 2001-05-29 | — | — | US | claimed |
| US-6124484-A | Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-26 | — | — | US | claimed |
| WO-2000004062-A1 | RECOVERY OF TRIARYLMETHYL HALIDE PROTECTING GROUPS CLEAVED DURING OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2000-01-27 | — | — | WO | claimed |
| CN-107643351-A | A kind of method of bromo-succinimide and succimide content in detection sodium ozagrel bulk drug | 浙江科瑞医药科技有限公司 | 2018-01-30 | — | — | CN | disclosed |
| CN-103070861-A | Pharmaceutical composition and application of same in preparation of medicines used for treating cerebrovascular diseases | JIANGSU SIMCERE PHARM RES CO | 2013-05-01 | — | — | CN | disclosed |
| WO-2008079988-A9 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2011-05-12 | — | — | WO | disclosed |
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | AIKAWA MINA | 2010-08-26 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| EP-2125755-A2 | QUINAZOLINES FOR PDK1 INHIBITION | Novartis Ag (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008079988-A2 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-7235575-B2 | Guanidine mimics as factor Xa inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-06-26 | — | — | US | disclosed |
| US-5064842-A | Thromboxane Synthetase Inhibitors | JOHN WYETH & BROTHER LIMITED (GB) | 1991-11-12 | — | — | US | disclosed |
| EP-0428849-A2 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-29 | — | — | EP | disclosed |
| EP-0320984-A2 | 1,4-Dihydropyridine derivatives | FUJIREBIO INC. (JP) | 1989-06-21 | — | — | EP | disclosed |
| US-4831045-A | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1989-05-16 | — | — | US | disclosed |
| CN-88103408-A | Process for preparing (1H-oxazol-1-ylmethyl) substituted benzotriazole derivatives | — | 1988-12-14 | — | — | CN | disclosed |
| US-4791126-A | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredients | ONO PHARMACEUTICAL CO., LTD. (JP) | 1988-12-13 | — | — | US | disclosed |
| EP-0047109-B1 | RHODANINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND ALDOSE REDUCTASE INHIBITOR CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 1985-01-02 | — | — | EP | disclosed |
| US-4464382-A | Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216767-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | CYP11B1 2219/4885CYP11B2 2481/4885CYP19A1 2090/4885 |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | CYP11B1 1274/4885CYP11B2 1634/4885CYP19A1 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.